ArticleJournal of hematology & oncology2022

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.

Narendranath Epperla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.